Literature DB >> 22673056

Pathological vascular invasion and tumor differentiation predict cancer recurrence in stage IA non-small-cell lung cancer after complete surgical resection.

Yoshihisa Shimada1, Hisashi Saji, Koichi Yoshida, Masatoshi Kakihana, Hidetoshi Honda, Masaharu Nomura, Jitsuo Usuda, Naohiro Kajiwara, Tatsuo Ohira, Norihiko Ikeda.   

Abstract

INTRODUCTION: The appropriate therapeutic strategy and postoperative management for patients with stage IA non-small-cell lung cancer (NSCLC) still remain a matter of debate because of the prognostic heterogeneity of this population, including the risk of cancer recurrence. The objective of the current study was to identify the clinicopathological factors that affect overall prognosis and cancer recurrence of stage IA NSCLC.
METHODS: We reviewed the data of 532 patients in whom complete resection of stage IA NSCLC had been performed. Overall survival and recurrence-free proportion (RFP) were estimated using the Kaplan-Meier method. RFP was estimated from the date of the primary tumor resection to the date of the first recurrence or last follow-up. We performed univariate and multivariate analyses to determine the independent prognostic factors.
RESULTS: On multivariate analyses, three variables were shown to be independently significant recurrence risk factors: histological differentiation (hazard ratio [HR] = 1.925), blood-vessel invasion (HR = 1.712), and lymph-vessel invasion (HR = 1.751). On subgroup analyses combining these risk factors, the 5-year RFP was 91.3% for patients with no risk factors, 79.5% for those with either poorly differentiated carcinoma or vascular invasion, (p < 0.001 for both), and 62.9% for those with both poorly differentiated carcinoma and vascular invasion (p = 0.068).
CONCLUSION: These results indicated that vascular invasion and tumor differentiation have a significant impact on the prediction of cancer recurrence in patients with stage IA NSCLC. Patients with these predictive factors of recurrence may be good candidates for adjuvant chemotherapy.

Entities:  

Mesh:

Year:  2012        PMID: 22673056     DOI: 10.1097/JTO.0b013e31825cca6e

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  31 in total

1.  MicroRNA-related single-nucleotide polymorphism of XPO5 is strongly correlated with the prognosis and chemotherapy response in advanced non-small-cell lung cancer patients.

Authors:  Ji-Qun Geng; Xiao-Chen Wang; Long-Fei Li; Jun Zhao; Song Wu; Gui-Ping Yu; Kou-Jun Zhu
Journal:  Tumour Biol       Date:  2015-09-10

2.  Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools.

Authors:  Alyson L Mahar; Carolyn Compton; Lisa M McShane; Susan Halabi; Hisao Asamura; Ramon Rami-Porta; Patti A Groome
Journal:  J Thorac Oncol       Date:  2015-11       Impact factor: 15.609

3.  Risk analyses of N2 lymph-node metastases in patients with T1 non-small cell lung cancer: a multi-center real-world observational study in China.

Authors:  Bing Chen; Wenjie Xia; Zhongqiu Wang; Heng Zhao; Xiaofei Li; Lunxu Liu; Yang Liu; Jian Hu; Xiangning Fu; Yin Li; Yijun Xu; Deruo Liu; Haiying Yang; Lin Xu; Feng Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-19       Impact factor: 4.553

4.  Elevated integrin α6β4 expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer.

Authors:  Rachel L Stewart; Dava West; Chi Wang; Heidi L Weiss; Tamas Gal; Eric B Durbin; William O'Connor; Min Chen; Kathleen L O'Connor
Journal:  Hum Pathol       Date:  2016-04-20       Impact factor: 3.466

5.  Prognostic value of the frequency of vascular invasion in stage I non-small cell lung cancer.

Authors:  Satoshi Okada; Shinjiro Mizuguchi; Nobuhiro Izumi; Hiroaki Komatsu; Michihito Toda; Kantaro Hara; Takahiro Okuno; Toshihiko Shibata; Hideki Wanibuchi; Noritoshi Nishiyama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-10-13

6.  Tumor spread through air space, the clinical implications for T factor and effects on the disease recurrence and prognosis.

Authors:  Takahiro Nakajima; Junichi Morimoto; Ichiro Yoshino
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

7.  Nomograms for predicting recurrence and survival of invasive pathological stage IA non-small cell lung cancer treated by video assisted thoracoscopic surgery lobectomy.

Authors:  Haiqing Chen; Xizhao Sui; Fan Yang; Jun Liu; Jun Wang
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

8.  Identification of the methylation of p14ARF promoter as a novel non-invasive biomarker for early detection of lung cancer.

Authors:  L Li; Y Shen; M Wang; D Tang; Y Luo; W Jiao; Z Wang; R Yang; K Tian
Journal:  Clin Transl Oncol       Date:  2013-10-24       Impact factor: 3.405

9.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Authors:  Ramón Rami-Porta; Hisao Asamura; Peter Goldstraw
Journal:  Transl Lung Cancer Res       Date:  2015-08

10.  Regulatory mechanism of ZNF139 in multi-drug resistance of gastric cancer cells.

Authors:  Yong Li; Bi-bo Tan; Qun Zhao; Li-qiao Fan; Yü Liu; Dong Wang
Journal:  Mol Biol Rep       Date:  2014-02-11       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.